• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishDashboard
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI employees
    Legal
    Terms of usePrivacy policyCookie policy

    CEO Vaddi Krishna bought $467,438 worth of shares (675,000 units at $0.69), increasing direct ownership by 51% to 1,999,296 units (SEC Form 4)

    3/27/25 4:37:44 PM ET
    $PRLD
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Get the next $PRLD alert in real time by email
    SEC FORM 4 SEC Form 4
    FORM 4 UNITED STATES SECURITIES AND EXCHANGE COMMISSION
    Washington, D.C. 20549

    STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

    Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
    or Section 30(h) of the Investment Company Act of 1940
    OMB APPROVAL
    OMB Number: 3235-0287
    Estimated average burden
    hours per response: 0.5
      
    Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).
      
    Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.
    1. Name and Address of Reporting Person*
    Vaddi Krishna

    (Last) (First) (Middle)
    C/O PRELUDE THERAPEUTICS INCORPORATED
    175 INNOVATION BOULEVARD

    (Street)
    WILMINGTON DE 19805

    (City) (State) (Zip)
    2. Issuer Name and Ticker or Trading Symbol
    Prelude Therapeutics Inc [ PRLD ]
    5. Relationship of Reporting Person(s) to Issuer
    (Check all applicable)
    X Director 10% Owner
    X Officer (give title below) Other (specify below)
    CEO
    3. Date of Earliest Transaction (Month/Day/Year)
    03/25/2025
    4. If Amendment, Date of Original Filed (Month/Day/Year)
    6. Individual or Joint/Group Filing (Check Applicable Line)
    X Form filed by One Reporting Person
    Form filed by More than One Reporting Person
    Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
    1. Title of Security (Instr. 3) 2. Transaction Date (Month/Day/Year) 2A. Deemed Execution Date, if any (Month/Day/Year) 3. Transaction Code (Instr. 8) 4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5) 5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4) 6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 7. Nature of Indirect Beneficial Ownership (Instr. 4)
    Code V Amount (A) or (D) Price
    Common Stock 03/25/2025 P 675,000 A $0.6925 1,999,296 D
    Common Stock 423,655 I By Trust(1)
    Common Stock 551,774 I By Trust(2)
    Common Stock 551,776 I By Trust(3)
    Common Stock 142,553 I See footnote(4)
    Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned
    (e.g., puts, calls, warrants, options, convertible securities)
    1. Title of Derivative Security (Instr. 3) 2. Conversion or Exercise Price of Derivative Security 3. Transaction Date (Month/Day/Year) 3A. Deemed Execution Date, if any (Month/Day/Year) 4. Transaction Code (Instr. 8) 5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5) 6. Date Exercisable and Expiration Date (Month/Day/Year) 7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4) 8. Price of Derivative Security (Instr. 5) 9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4) 10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 11. Nature of Indirect Beneficial Ownership (Instr. 4)
    Code V (A) (D) Date Exercisable Expiration Date Title Amount or Number of Shares
    Explanation of Responses:
    1. The Reporting Person is a beneficiary of the Dolphin City Trust. The Reporting Person disclaims beneficial ownership of such securities except to the extent of his pecuniary interest therein, and the inclusion of these securities in this report shall not be deemed an admission of beneficial ownership of such securities for purposes of Section 16 or for any other purposes.
    2. The Reporting Person is the investment advisor of the Brocade Trust. The Reporting Person disclaims beneficial ownership of such securities except to the extent of his pecuniary interest therein, and the inclusion of these securities in this report shall not be deemed an admission of beneficial ownership of such securities for purposes of Section 16 or for any other purposes.
    3. The Reporting Person is the investment advisor of the Blue Sky Trust. The Reporting Person disclaims beneficial ownership of such securities except to the extent of his pecuniary interest therein, and the inclusion of these securities in this report shall not be deemed an admission of beneficial ownership of such securities for purposes of Section 16 or for any other purposes.
    4. The Reporting Person is the manager of Sidus Ventures LLC. The Reporting Person disclaims beneficial ownership of such securities except to the extent of his pecuniary interest therein, and the inclusion of these securities in this report shall not be deemed an admission of beneficial ownership of such securities for purposes of Section 16 or for any other purposes.
    Remarks:
    /s/ Bryant D. Lim, Attorney-in-Fact 03/27/2025
    ** Signature of Reporting Person Date
    Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
    * If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
    ** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
    Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
    Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
    Get the next $PRLD alert in real time by email

    Chat with this insight

    Save time and jump to the most important pieces.

    Recent Analyst Ratings for
    $PRLD

    DatePrice TargetRatingAnalyst
    9/19/2024$5.00Neutral → Buy
    H.C. Wainwright
    6/20/2024$3.00Equal Weight → Underweight
    Barclays
    3/13/2024$7.00Mkt Outperform
    JMP Securities
    2/20/2024$5.00Buy → Neutral
    H.C. Wainwright
    12/19/2023$10.00 → $4.00Equal-Weight → Underweight
    Morgan Stanley
    11/21/2022$8.00 → $6.00Neutral → Underperform
    BofA Securities
    9/9/2022$19.00 → $11.00Overweight → Equal-Weight
    Morgan Stanley
    7/29/2022$9.00Buy
    Jefferies
    More analyst ratings

    $PRLD
    Press Releases

    Fastest customizable press release news feed in the world

    See more
    • Prelude Therapeutics to Participate in Upcoming Healthcare Conferences

      WILMINGTON, Del., June 02, 2025 (GLOBE NEWSWIRE) -- Prelude Therapeutics Incorporated (Prelude) (NASDAQ:PRLD), a clinical-stage precision oncology company, announced today that the Company will participate in two upcoming healthcare conferences in June. Jefferies Global Healthcare Conference 2025:On Thursday, June 5, 2025, at 3:10 p.m. ET, Kris Vaddi, Ph.D., Chief Executive Officer of Prelude will participate in a fireside chat. Goldman Sachs 46th Annual Global Healthcare Conference:On Wednesday, June 11, 2025, at 9:20 a.m. ET, Kris, Vaddi, Ph.D., Chief Executive Officer of Prelude will participate in a fireside chat. Live webcasts of the fireside chats can be accessed on the Company's

      6/2/25 7:30:00 AM ET
      $PRLD
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Prelude Therapeutics Reports First Quarter 2025 Financial Results and Provides Corporate Update

      PRT3789 monotherapy and combination with docetaxel escalation enrollment is complete and the Company plans to present updated results in the second half of 2025 Enrollment of the Phase 1 study of Prelude's once daily, oral SMARCA2 degrader, PRT7732 is advancing rapidly, and an initial data update is anticipated in the second half of 2025 Current cash runway into the second quarter of 2026 with $103.1 million in cash, cash equivalents, restricted cash and marketable securities as of March 31, 2025  WILMINGTON, Del., May 06, 2025 (GLOBE NEWSWIRE) -- Prelude Therapeutics Incorporated (NASDAQ:PRLD), a clinical-stage precision oncology company, today reported its financial results for

      5/6/25 4:05:00 PM ET
      $PRLD
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Prelude Therapeutics to Participate in Citizens Life Sciences Conference

      WILMINGTON, Del., May 01, 2025 (GLOBE NEWSWIRE) -- Prelude Therapeutics Incorporated (Prelude) (NASDAQ:PRLD), a clinical-stage precision oncology company, announced today that the Company will participate in the Citizens Life Sciences Conference taking place in New York on May 7, 2025. On Wednesday, May 7, 2025, at 11:00 a.m. ET, Kris Vaddi, Ph.D., Chief Executive Officer of Prelude, Jane Huang, M.D., President and Chief Medical Officer, and Peggy Scherle, Ph.D., Chief Scientific Officer will participate in a fireside chat. A live webcast of the fireside chat can be accessed on the Company's website under Events and Presentations. The recording will be archived and available on the Compa

      5/1/25 7:30:00 AM ET
      $PRLD
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $PRLD
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • Chief Chemistry Officer Combs Andrew bought $69,250 worth of shares (100,000 units at $0.69), increasing direct ownership by 26% to 480,123 units (SEC Form 4)

      4 - Prelude Therapeutics Inc (0001678660) (Issuer)

      3/27/25 4:40:54 PM ET
      $PRLD
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • CEO Vaddi Krishna bought $467,438 worth of shares (675,000 units at $0.69), increasing direct ownership by 51% to 1,999,296 units (SEC Form 4)

      4 - Prelude Therapeutics Inc (0001678660) (Issuer)

      3/27/25 4:37:44 PM ET
      $PRLD
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • CEO Vaddi Krishna bought $14,909 worth of shares (20,416 units at $0.73), increasing direct ownership by 2% to 1,324,296 units (SEC Form 4)

      4 - Prelude Therapeutics Inc (0001678660) (Issuer)

      3/24/25 5:03:10 PM ET
      $PRLD
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $PRLD
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    See more
    • Prelude Therapeutics upgraded by H.C. Wainwright with a new price target

      H.C. Wainwright upgraded Prelude Therapeutics from Neutral to Buy and set a new price target of $5.00

      9/19/24 7:51:24 AM ET
      $PRLD
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Prelude Therapeutics downgraded by Barclays with a new price target

      Barclays downgraded Prelude Therapeutics from Equal Weight to Underweight and set a new price target of $3.00

      6/20/24 7:37:20 AM ET
      $PRLD
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • JMP Securities initiated coverage on Prelude Therapeutics with a new price target

      JMP Securities initiated coverage of Prelude Therapeutics with a rating of Mkt Outperform and set a new price target of $7.00

      3/13/24 7:41:41 AM ET
      $PRLD
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $PRLD
    Leadership Updates

    Live Leadership Updates

    See more
    • Prelude Therapeutics Announces First Quarter 2022 Financial Results and Operations Update

      Prelude remains on track for clinical data readouts and next steps for the PRMT5 program, MCL1 inhibitor PRT1419, and CDK9 inhibitor PRT2527 in 2H2022 Strong cash and cash equivalents of $266.2 million as of March 31, 2022, expected to fund operations into 2H2024 WILMINGTON, Del., May 10, 2022 (GLOBE NEWSWIRE) -- Prelude Therapeutics Incorporated ("Prelude") (NASDAQ:PRLD), a clinical-stage precision oncology company, today reported financial results for the first quarter ended March 31, 2022, and provided an update on recent clinical and development pipeline progress. "Prelude continues to make great progress in discovering and advancing a diverse pipeline of differentiated small molecu

      5/10/22 8:00:00 AM ET
      $PRLD
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Prelude Therapeutics Reports Full Year 2021 Financial Results

      Significant progress achieved in 2021: Pipeline now includes six internally discovered small molecule compounds targeting clinically validated pathways in cancers with underserved patients Objectives for 2022: Focused on demonstrating proof-of-concept clinical data for lead pipeline compounds and continued advancement of Prelude's diverse precision oncology pipeline Cash runway guidance extended to 2H/2024 WILMINGTON, Del., March 16, 2022 (GLOBE NEWSWIRE) -- Prelude Therapeutics Incorporated (NASDAQ:PRLD), a clinical-stage precision oncology company, today reported its financial results for the fiscal year ended December 31, 2021. "With Prelude's core competencies in cancer biology an

      3/16/22 7:30:00 AM ET
      $PRLD
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Jane Huang, M.D., Joins Prelude Therapeutics as President and Chief Medical Officer

      WILMINGTON, Del., March 09, 2022 (GLOBE NEWSWIRE) -- Prelude Therapeutics Incorporated (NASDAQ:PRLD) a clinical-stage precision oncology company, today announced that Jane Huang, M.D., has been appointed to the newly created position of President and Chief Medical Officer, effective on April 4, 2022. Dr. Huang is currently Chief Medical Officer, Hematology, at BeiGene, Ltd., a global, science-driven biotechnology company developing oral small molecules and monoclonal antibodies for cancer. "We are pleased to announce that Dr. Huang will be joining Prelude. Jane's deep experience in oncology drug development and her strategic leadership throughout the lifecycle of multiple products resulti

      3/9/22 8:00:00 AM ET
      $PRLD
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $PRLD
    SEC Filings

    See more
    • Amendment: SEC Form SCHEDULE 13D/A filed by Prelude Therapeutics Incorporated

      SCHEDULE 13D/A - Prelude Therapeutics Inc (0001678660) (Subject)

      6/13/25 5:21:09 PM ET
      $PRLD
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Prelude Therapeutics Incorporated filed SEC Form 8-K: Leadership Update, Submission of Matters to a Vote of Security Holders

      8-K - Prelude Therapeutics Inc (0001678660) (Filer)

      6/13/25 4:10:27 PM ET
      $PRLD
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Amendment: SEC Form SCHEDULE 13G/A filed by Prelude Therapeutics Incorporated

      SCHEDULE 13G/A - Prelude Therapeutics Inc (0001678660) (Subject)

      5/15/25 5:20:50 PM ET
      $PRLD
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $PRLD
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • SEC Form 4 filed by Director Baker Bros. Advisors Lp

      4 - Prelude Therapeutics Inc (0001678660) (Issuer)

      6/13/25 4:45:31 PM ET
      $PRLD
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form 3 filed by new insider Scherer Paul C

      3 - Prelude Therapeutics Inc (0001678660) (Issuer)

      6/13/25 4:43:00 PM ET
      $PRLD
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form 4 filed by Director Sandor Victor

      4 - Prelude Therapeutics Inc (0001678660) (Issuer)

      6/13/25 4:15:50 PM ET
      $PRLD
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $PRLD
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    See more
    • SEC Form SC 13G/A filed by Prelude Therapeutics Incorporated (Amendment)

      SC 13G/A - Prelude Therapeutics Inc (0001678660) (Subject)

      2/13/24 1:34:34 PM ET
      $PRLD
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form SC 13G/A filed by Prelude Therapeutics Incorporated (Amendment)

      SC 13G/A - Prelude Therapeutics Inc (0001678660) (Subject)

      2/12/24 5:30:07 PM ET
      $PRLD
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form SC 13G/A filed by Prelude Therapeutics Incorporated (Amendment)

      SC 13G/A - Prelude Therapeutics Inc (0001678660) (Subject)

      2/12/24 4:26:50 PM ET
      $PRLD
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $PRLD
    Financials

    Live finance-specific insights

    See more
    • Prelude Therapeutics' SMARCA2 Degrader PRT3789 Demonstrated Promising Initial Clinical Activity and Safety Profile in Phase 1 Trial

      -  Encouraging signs of anti-tumor activity including objective responses observed in patients with SMARCA4-mutated non-small cell lung cancer (NSCLC) and esophageal cancer in early PRT3789 monotherapy dose escalation -  At doses studied to date, PRT3789 was generally well-tolerated with no dose-limiting toxicities or study drug-related serious adverse events -  Company to host investor conference call and webcast on Friday, September 13, 2024 at 12:00 PM EST WILMINGTON, Del., Sept. 13, 2024 (GLOBE NEWSWIRE) -- Prelude Therapeutics Incorporated (NASDAQ:PRLD), a clinical-stage precision oncology company, today announced the first interim clinical

      9/13/24 10:00:00 AM ET
      $PRLD
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Prelude Therapeutics Announces Publication of Abstract for Presentation at the European Society of Medical Oncology (ESMO) Congress 2024

      PRT3789, a novel, highly-selective SMARCA2 degrader in patients with advanced solid tumors with a SMARCA4 mutation oral session presentation: September 13, 2024, 4:00 PM CEST (10:00 AM EST) Prelude will host an investor webcast on September 13, 2024, 6:00 PM CEST, (12:00 PM EST) WILMINGTON, Del., Sept. 09, 2024 (GLOBE NEWSWIRE) -- Prelude Therapeutics Incorporated (NASDAQ:PRLD) ("Prelude" or the "Company"), a clinical-stage precision oncology company, today announced the publication of an abstract regarding PRT3789 at the European Society of Medical Oncology (ESMO) Congress 2024 taking place in Barcelona, Spain September 13-17, 2024. The abstract can be found on the ESMO 2024 website

      9/9/24 7:30:00 AM ET
      $PRLD
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Prelude Therapeutics Announces Third Quarter 2021 Financial Results and Operations Update

      PRT543 and PRT811 Demonstrate Favorable Safety Profile, Tolerability and Evidence of Preliminary Clinical Activity in Phase 1 Dose Escalation in Unselected Patients Phase 1 Dose Expansion Ongoing in Biomarker-Selected Solid Tumor and Hematologic Malignancy Expansion Cohorts for PRT543; Dose Expansion Portion of Phase 1 Trial of PRT811 to Commence 4Q21 with Data Readouts Anticipated for Both Programs in 2022 PRT2527 IND Cleared by FDA; Phase 1 Clinical Trial Evaluating IV Monotherapy in Patients with Selected Solid Tumors Anticipated to Begin by Year-End Strong Cash, Cash Equivalents and Marketable Securities Position of $320 Million to Support Clinical and Discovery Pipeline Advance

      11/12/21 8:00:00 AM ET
      $PRLD
      Biotechnology: Pharmaceutical Preparations
      Health Care